ReviewJournal of clinical medicine2025
Diagnosing Ulcerative Colitis: Should We Go Beyond the Surface?
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- 20(R)-Rg3 derived from ginseng fibrous roots ameliorates DSS-induced colitis via selective modulation of glucocorticoid receptor signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Back to the Future: Repurposing Metformin, a Metabolically Active Drug, to Treat Mild-to-Moderate Ulcerative Colitis.Metabolites · 2026Review
- Constipation in Ulcerative Colitis: An Underestimated Problem.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation of the large bowel. However, by conducting a literature search, it emerges that, although being considered a primary mucosal disorder in a subset of patients, the inflammatory process may extend beyond the mucosal surface. For this reason, we reviewed the pertinent literature to evaluate the evidence related to the aforementioned topic. The literature analysis confirmed that, although ulcerative colitis has to be defined as a primary mucosal disease due to its consistent mucosal onset, it can involve deeper layers of the colonic wall. The inefficacy of anti-inflammatory therapies in a considerable proportion of patients, along with the lack of histologic healing and the persistence of inflammatory status and colonic wall thickening at imaging despite mucosal healing, has led to consider an extension of the disease process beyond the mucosal layer. The recent application of more accurate diagnostic tools, both histological and radiological (i.e., intestinal ultrasound and magnetic resonance), has the potential to underline the early signs of disease extension and progression in order to improve ulcerative colitis clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.